Fig 1: Immunohistochemical staining of CHEK2 protein. (a) Staining for normal gland (positive control: the nucleus was positive for CHEK2). (b) Staining for PPGL tumor tissue with RET mutation (positive control: the nucleus was positive for CHEK2), (c) for Patient 1 (negative for CHEK2), (d) for Patient 2 (negative for CHEK2), (e) for Patient 3 (negative for CHEK2), and (f) for Patient 4 (the nucleus was negative but partial cytoplasm was weak positive for CHEK2).
Fig 2: The representative images of IHC staining of five ARGs from SYSUCC. (A) A2M; (B) CHEK2; (C) FOS; (D) PLAU; and (E) ELN. The representative images of IHC staining of four ARGs from Human Protein Atlas. (F) A2M; (G) CHEK2; (H) FOS; and (I) PLAU. (J) The IHC score of 5 ARGs.
Fig 3: The germline CHEK2 mutations detected by Sanger sequencing of these four patients. The red arrows indicate the mutation sites, (a) for Patient 1, (b) for Patient 2, (c) for Patient 3, and (d) for Patient 4.
Fig 4: The somatic CHEK2 mutations detected of three patients compared with the germline mutation sites. The other one patient' sufficient FFPE sample was not obtained. The red arrows indicate the mutation sites, (a) for Patient 1, (b) for Patient 2, and (c) for Patient 3. “B” means the germline sites from peripheral blood leukocytes, and “T” means the somatic sites from FFPE tumor tissues.
Fig 5: The pattern diagram of functional domain on CHEK2 gene and the location of the four detected mutations.
Supplier Page from Abcam for Anti-Chk2 antibody [EPR19482]